The WIZARD trial as a case study of flexible clinical trial design

被引:0
|
作者
Cook, Thomas D.
Benner, Rebecca J.
Fisher, Marian R.
机构
[1] Univ Wisconsin, Dept Biostat & Med Informat, Madison, WI 53726 USA
[2] Pfizer Global Res & Dev, New London, CT USA
来源
DRUG INFORMATION JOURNAL | 2006年 / 40卷 / 03期
关键词
composite end points; event-driven trials; group sequential testing; adaptive design; conditional power;
D O I
暂无
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The design of a randomized, controlled, confirmatory efficacy clinical trial is influenced by multiple competing factors, including ethical, scientific, economic and regulatory interest. Design elements, including choice of end points, study duration, and interim monitoring plans, need to be adapted to specific circumstances. They Weekly Intervention With Zithromax for Atherosclerosis and Its Related Disorders WIZARD) study design was initially intended to meet the sponsor's scientific goals while being subject to practical constraints. In response to changing circumstances, modifications to the study design were required. The WIZARD trial demonstrates the substantial flexibility in the design and conduct of group sequential randomized trials not only during the design stage but also after the trial is under way, effectively satisfying evolving and competing demands while preserving the statistical and scientific validity of the study.
引用
收藏
页码:345 / 353
页数:9
相关论文
共 50 条
  • [1] The WIZARD Trial as a Case Study of Flexible Clinical Trial Design
    Thomas D. Cook
    Rebecca J. Benner
    Marian R. Fisher
    [J]. Drug information journal : DIJ / Drug Information Association, 2006, 40 (3): : 345 - 353
  • [2] A regulatory view on adaptive/flexible clinical trial design
    Hung, H. M. James
    O'neill, Robert T.
    Wang, Sue-Jane
    Lawrence, John
    [J]. BIOMETRICAL JOURNAL, 2006, 48 (04) : 565 - 573
  • [3] Flexible design clinical trial methodology in regulatory applications
    Hung, H. M. James
    Wang, Sue-Jane
    O'Neill, Robert
    [J]. STATISTICS IN MEDICINE, 2011, 30 (13) : 1519 - 1527
  • [4] Improving early phase oncology clinical trial design: A case study
    Phillips, Alan J.
    Clark, Timothy P.
    [J]. PHARMACEUTICAL STATISTICS, 2022, 21 (06) : 1370 - 1375
  • [5] Design evaluation for a population pharmacokinetic study using clinical trial simulations: a case study
    Kowalski, KG
    Hutmacher, MM
    [J]. STATISTICS IN MEDICINE, 2001, 20 (01) : 75 - 91
  • [6] Design of a population pharmacokinetic study using clinical trial simulations: A case study.
    Kowalski, KG
    Hutmacher, MM
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 67 (02) : 115 - 115
  • [7] The importance of the study design: from the case report to the randomised controlled clinical trial
    Glenny, Anne-Marie
    Nieri, Michele
    Worthington, Helen
    Esposito, Marco
    [J]. EUROPEAN JOURNAL OF ORAL IMPLANTOLOGY, 2008, 1 (04) : 317 - 321
  • [8] The Clinical Trial Design
    Naqvi, Haider A.
    [J]. JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2014, 24 (04): : 221 - 223
  • [9] Flexible trial design in a rare condition
    Veronica Moroz
    Keith Wheatley
    Martin McCabe
    [J]. Trials, 14 (Suppl 1)
  • [10] Understanding potential participation barriers to improve trial design and outcomes: clinical trial simulation in palmoplantar pustulosis as a case study
    Boisvert-Huneault, Christian
    Trigos Herraez, David
    Pinter, Andreas
    Kobayashi, Satomi
    Bell, Stacie
    Kallsen, Kimberley
    Gloede, Tristan
    Yagi, Nobutaka
    Brunette, Steven
    Datsenko, Yakov
    Baehner, Frank
    Clerisme-Beaty, Emmanuelle
    Van de Kerkhof, Peter
    [J]. BMJ OPEN, 2023, 13 (04):